[go: up one dir, main page]

MX2015006548A - Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2. - Google Patents

Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2.

Info

Publication number
MX2015006548A
MX2015006548A MX2015006548A MX2015006548A MX2015006548A MX 2015006548 A MX2015006548 A MX 2015006548A MX 2015006548 A MX2015006548 A MX 2015006548A MX 2015006548 A MX2015006548 A MX 2015006548A MX 2015006548 A MX2015006548 A MX 2015006548A
Authority
MX
Mexico
Prior art keywords
repeat domains
binding proteins
against her2
domains against
repeat
Prior art date
Application number
MX2015006548A
Other languages
English (en)
Other versions
MX366223B (es
Inventor
Ulrike Fiedler
Heike Strobel
Igancio Dolado
Original Assignee
Molecular Partners Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners Ag filed Critical Molecular Partners Ag
Publication of MX2015006548A publication Critical patent/MX2015006548A/es
Publication of MX366223B publication Critical patent/MX366223B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cell Biology (AREA)

Abstract

La presente invención se refiere a una proteína vinculante o de unión, recombinante, que comprende al menos un primer y un segundo dominio de repetición, en donde cada uno de dichos dos dominios de repetición se vincula o une a la región extracelular del HER2 y en donde dichos dominios de repetición se vinculan o unen covalentemente.
MX2015006548A 2012-11-30 2013-12-02 Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2. MX366223B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12195156.0A EP2738180A1 (en) 2012-11-30 2012-11-30 Binding proteins comprising at least two binding domains against HER2.
PCT/EP2013/075290 WO2014083208A1 (en) 2012-11-30 2013-12-02 Binding proteins comprising at least two repeat domains against her2

Publications (2)

Publication Number Publication Date
MX2015006548A true MX2015006548A (es) 2015-10-15
MX366223B MX366223B (es) 2019-07-03

Family

ID=47257683

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015006548A MX366223B (es) 2012-11-30 2013-12-02 Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2.

Country Status (11)

Country Link
US (1) US10370414B2 (es)
EP (2) EP2738180A1 (es)
JP (1) JP6410724B2 (es)
KR (1) KR102290592B1 (es)
CN (1) CN104918959A (es)
AU (2) AU2013351096C9 (es)
CA (1) CA2892747C (es)
HK (1) HK1211297A1 (es)
MX (1) MX366223B (es)
RU (1) RU2664464C9 (es)
WO (1) WO2014083208A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
CA2818969C (en) * 2010-11-26 2020-04-14 Molecular Partners Ag Improved n-terminal capping modules for designed ankyrin repeat proteins
AU2013331763B2 (en) * 2012-10-15 2018-02-15 Universitat Zurich Bispecific HER2 ligands for cancer therapy
CN105209483B (zh) 2013-05-31 2021-07-27 分子组合公司 与肝细胞生长因子结合的设计锚蛋白重复蛋白
WO2015077891A1 (en) 2013-11-27 2015-06-04 Zymeworks Inc. Bispecific antigen-binding constructs targeting her2
WO2016082044A1 (en) 2014-11-27 2016-06-02 Zymeworks Inc. Methods of using bispecific antigen-binding constructs targeting her2
EP3253785B1 (en) 2015-02-06 2019-04-10 Navigo Proteins Gmbh Novel egfr binding proteins
CN107454904A (zh) 2015-04-02 2017-12-08 分子组合公司 对血清白蛋白具有结合特异性的经设计的锚蛋白重复结构域
WO2017009421A1 (en) 2015-07-16 2017-01-19 Scil Proteins Gmbh Novel immunoglobulin-binding proteins and their use in affinity purification
US10584152B2 (en) 2015-07-20 2020-03-10 Navigo Proteins Gmbh Binding proteins based on di-ubiquitin muteins and methods for generation
WO2017013129A1 (en) * 2015-07-20 2017-01-26 Scil Proteins Gmbh Her2 binding proteins based on di-ubiquitin muteins
US11813336B2 (en) 2016-05-04 2023-11-14 Navigo Proteins Gmbh Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
RU2627215C1 (ru) * 2016-05-24 2017-08-03 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Нижегородский государственный университет им. Н.И. Лобачевского" Рекомбинантный таргетный токсин, специфичный к клеткам, экспрессирующим рецептор her2
CN117736281A (zh) 2016-08-11 2024-03-22 瑞普利金公司 用于亲和色谱的碱性稳定性fc结合蛋白
US10717772B2 (en) * 2016-09-22 2020-07-21 Molecular Partners Ag Recombinant binding proteins targeting HER2 and serum albumin, and their uses
KR20250072712A (ko) 2016-12-02 2025-05-26 앤젤레스 테라퓨틱스, 인코포레이티드 합성 면역 수용체 및 이의 사용 방법
US11414466B2 (en) 2017-11-07 2022-08-16 Navigo Proteins Gmbh Fusion proteins with specificity for ED-B and long serum half-life for diagnosis or treatment of cancer
WO2020127224A1 (en) 2018-12-18 2020-06-25 Navigo Proteins Gmbh Novel folr1 specific binding proteins for cancer diagnosis and treatment
CA3138805A1 (en) * 2019-06-04 2020-12-10 Johannes Schilling Designed ankyrin repeat domain with improved stability
UY38739A (es) 2019-06-04 2020-12-31 Molecular Partners Ag Proteínas multiespecíficas
KR20220016942A (ko) * 2019-06-04 2022-02-10 몰리큘라 파트너스 아게 재조합 fap 결합 단백질 및 이의 용도
US20220298212A1 (en) * 2019-06-04 2022-09-22 Molecular Partners Ag Recombinant 4-1bb binding proteins and their use
KR20250090381A (ko) 2019-07-26 2025-06-19 주식회사유한양행 항-her2/항-4-1bb 이중 특이 항체 및 이의 용도
WO2021116469A2 (en) * 2019-12-11 2021-06-17 Molecular Partners Ag Recombinant peptide-mhc complex binding proteins and their generation and use
EP4146691A1 (en) 2020-05-06 2023-03-15 Molecular Partners AG Novel ankyrin repeat binding proteins and their uses
US20240279309A1 (en) * 2020-05-14 2024-08-22 Molecular Partners Ag Recombinant cd40 binding proteins and their use
JP2023528204A (ja) 2020-05-14 2023-07-04 モレキュラー パートナーズ アクチェンゲゼルシャフト 多選択性タンパク質
AU2021403833A1 (en) 2020-12-16 2023-07-27 Molecular Partners Ag Novel slow-release prodrugs
EP4304731A1 (en) 2021-03-09 2024-01-17 Molecular Partners AG Novel darpin based multi-specific t-cell engagers
AU2022233791A1 (en) 2021-03-09 2023-09-28 Molecular Partners Ag Novel darpin based cd123 engagers
CA3211248A1 (en) 2021-03-09 2022-09-15 Nina RESCHKE Novel darpin based cd33 engagers
EP4305063A1 (en) 2021-03-09 2024-01-17 Molecular Partners AG Protease cleavable prodrugs
WO2023110983A1 (en) 2021-12-14 2023-06-22 Molecular Partners Ag Designed repeat domains with dual binding specificity and their use
EP4565606A1 (en) 2022-08-01 2025-06-11 Molecular Partners AG Charge modified designed repeat domains and their use
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules
EP4673159A1 (en) 2023-02-27 2026-01-07 Molecular Partners AG Darpins for use in reducing renal accumulation of drugs
WO2024251628A1 (en) 2023-06-06 2024-12-12 Molecular Partners Ag Recombinant cd16a binding proteins and their use
WO2025146491A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
ATE321849T1 (de) 1997-04-23 2006-04-15 Univ Zuerich Verfahren zur erkennung von nucleinsäuremolekülen codierend für (poly)peptide, welche mit zielmolekülen interagieren
WO2000032823A1 (en) 1998-12-02 2000-06-08 Phylos, Inc. Dna-protein fusions and uses thereof
CA2421447C (en) 2000-09-08 2012-05-08 Universitat Zurich Collections of repeat proteins comprising repeat modules
BRPI0510716A (pt) * 2004-05-05 2007-11-20 Merrimack Pharmaceuticals Inc uso de um agente de ligação bi-especìfico, agente de ligação bi-especìfico, composição de um agente de ligação bi-especìfico, e, kit
KR20180091967A (ko) * 2004-07-22 2018-08-16 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
DE602006010386D1 (en) 2005-07-08 2009-12-24 Univ Zuerich Phagen-display mittels cotranslationaler translokation von fusionspolypeptiden
CA2644712C (en) 2006-03-06 2016-09-13 Amunix, Inc. Unstructured recombinant polymers and uses thereof
NZ580670A (en) 2007-06-21 2011-09-30 Univ Muenchen Tech Biological active proteins having increased in vivo and/or vitro stability
WO2009040338A1 (en) 2007-09-24 2009-04-02 University Of Zürich Designed armadillo repeat proteins
AU2008328781A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
ES2836948T3 (es) 2008-11-03 2021-06-28 Molecular Partners Ag Proteínas de unión que inhiben la interacción del receptor de VEGF-A
TW201120210A (en) * 2009-11-05 2011-06-16 Hoffmann La Roche Glycosylated repeat-motif-molecule conjugates
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
CA2818969C (en) 2010-11-26 2020-04-14 Molecular Partners Ag Improved n-terminal capping modules for designed ankyrin repeat proteins
JP2014519808A (ja) 2011-04-29 2014-08-21 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ４／ｉｌ１３に結合する反復タンパク質及び使用
WO2012162418A1 (en) * 2011-05-23 2012-11-29 The University Of North Carolina At Chapel Hill Methods and compositions for heterodimeric targeting ligands
KR20150023957A (ko) 2012-06-28 2015-03-05 몰리큘라 파트너스 아게 혈소판-유래 성장인자에 결합하는 설계된 안키린 반복 단백질
AU2013331763B2 (en) 2012-10-15 2018-02-15 Universitat Zurich Bispecific HER2 ligands for cancer therapy
CN105209483B (zh) 2013-05-31 2021-07-27 分子组合公司 与肝细胞生长因子结合的设计锚蛋白重复蛋白

Also Published As

Publication number Publication date
EP2925784B1 (en) 2021-02-17
JP6410724B2 (ja) 2018-10-24
KR20150091138A (ko) 2015-08-07
EP2738180A1 (en) 2014-06-04
AU2013351096B2 (en) 2018-08-09
RU2664464C2 (ru) 2018-08-17
RU2015120663A (ru) 2017-01-10
HK1211297A1 (zh) 2016-05-20
AU2018256592A1 (en) 2018-11-22
BR112015012436A2 (pt) 2017-09-12
JP2015537044A (ja) 2015-12-24
AU2013351096C9 (en) 2019-01-31
AU2013351096A1 (en) 2015-07-09
EP2925784A1 (en) 2015-10-07
KR102290592B1 (ko) 2021-08-19
WO2014083208A1 (en) 2014-06-05
RU2664464C9 (ru) 2018-12-19
AU2013351096C1 (en) 2018-11-08
MX366223B (es) 2019-07-03
WO2014083208A9 (en) 2014-12-24
US10370414B2 (en) 2019-08-06
US20150299265A1 (en) 2015-10-22
CA2892747C (en) 2022-07-19
WO2014083208A8 (en) 2014-10-30
CA2892747A1 (en) 2014-06-05
CN104918959A (zh) 2015-09-16

Similar Documents

Publication Publication Date Title
MX366223B (es) Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2.
CY1119567T1 (el) Θεραπευτικα πεπτιδια
CY1122978T1 (el) Αντισωματα εναντι-vla-4
IN2012DN00640A (es)
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
PH12012502115A1 (en) Modified binding proteins inhibiting the vegf-a receptor interaction
PH12013502024A1 (en) Dual variable region antibody-like binding proteins having cross-over binding region orientation
NZ729044A (en) 4-1bb binding molecules
IN2015MN00139A (es)
MX2015011075A (es) Peptidos terapeuticos.
UA106900C2 (uk) Агоністичний dr5-зв'язувальний поліпептид
UA110049C2 (uk) ЛІКУВАННЯ ОСТЕОАРТРИТУ ІМУНОГЛОБУЛІНОВИМ ЗВ'ЯЗУВАЛЬНИМ БІЛКОМ З ПОДВІЙНИМ ВАРІАБЕЛЬНИМ ДОМЕНОМ, ЩО ЗВ'ЯЗУЄ IL-1α І IL-1β
EA201690314A1 (ru) Анти-garp-белок и его применения
MX342034B (es) Proteinas monovalentes que se unen a antigenos.
MX2012013406A (es) Variantes de union mejoradas anti-albumina serica.
MX2011008752A (es) Variantes de union a anti-albumina de suero mejoradas.
PH12014501818A1 (en) Pseudomonas aeruginosa pcrv binding single variable domain antibodies
PH12015500752A1 (en) Her3 antigen binding proteins binding to the beta-hairpin of her3
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
MX2015013803A (es) Proteina de fusion de enlace al cartilago.
MX2011008749A (es) Variantes de union a anti-albumina de suero mejoradas.
PH12019500677A1 (en) Cmet monoclonal binding agents, drug conjugates thereof and uses thereof
EA201390955A1 (ru) Слитый белок robo1-fc для применения в лечении гепатокарциномы
PH12016500111A1 (en) An immunoglobulin fc conjugate which maintains binding affinity of immunoglobulin fc fragment to fcrn
NZ731491A (en) Cd83 binding proteins and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration